Skip to contentM
Mangoceuticals, Inc.
M
MGRXMangoceuticals, Inc. Q1 2026 · 10-Q
Revenue$67.86K$67.86K−37.9% vs Q1 2025 Net Income-$3.40M-$3.40MN/M vs Q1 2025 EPS Diluted-$0.22-$0.22N/M vs Q1 2025 Gross Profit$29,001−53.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
Operating Cash Flow-$1,311,343N/M Margins · derivedGross margin42.7%−14.0 pt vs Q1 2025
Operating margin-4606.8%−420.0 pt vs Q1 2025
Net margin-5014.7%−587.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 19, 2026 · 49 d after period end